Wiley Wins High-Profile Drug Patent Case on Behalf of Generic Manufacturer
July 14, 2023
July 14, 2023
WASHINGTON, July 14 -- Wiley Rein, a law firm, issued the following news release:
On behalf of generic drug manufacturer Macleods Pharmaceuticals Ltd., Wiley Rein LLP helped persuade a federal court in Delaware to invalidate a patent for a widely used cardiovascular medication.
The U.S. District Court for the District of Delaware ruled that a patent held by Novartis for Entresto (U.S. Pat. No. 8,101,659), a heart-failure drug that earned billions of dollars worldwide in . . .
On behalf of generic drug manufacturer Macleods Pharmaceuticals Ltd., Wiley Rein LLP helped persuade a federal court in Delaware to invalidate a patent for a widely used cardiovascular medication.
The U.S. District Court for the District of Delaware ruled that a patent held by Novartis for Entresto (U.S. Pat. No. 8,101,659), a heart-failure drug that earned billions of dollars worldwide in . . .